PROCEPT BioRobotics has emerged as one of the most underrated robotics stocks heading into 2026, flying under the radar of many investors who remain fixated on larger surgical robotics players like Intuitive Surgical. The San Jose-based company, which specializes in robotic systems for urological procedures, has carved out a compelling niche in the medical robotics sector with its Aquablation therapy and AQUABEAM Robotic System. While the broader investment community debates the merits of established robotics giants, PROCEPT has quietly built a substantial installed base, grown its revenue at triple-digit rates, and positioned itself at the intersection of two powerful trends: an aging global population and the shift toward minimally invasive surgical procedures. The question of why PROCEPT BioRobotics deserves more attention from robotics-focused investors addresses several critical gaps in how the market evaluates emerging surgical robotics companies. Many analysts focus exclusively on revenue multiples or path to profitability without considering the strategic moat that comes from proprietary technology, surgeon adoption curves, and procedure volume growth.
PROCEPT’s Aquablation therapy represents a genuinely differentiated approach to treating benign prostatic hyperplasia (BPH), a condition affecting roughly half of all men over 50 and nearly 90 percent of men over 80. The company is not merely competing with other robotic systems””it is competing against traditional surgical approaches and pharmaceutical treatments, giving it a much larger addressable market than its current market capitalization suggests. By the end of this article, readers will understand the fundamental technology behind PROCEPT’s robotic platform, the financial trajectory that has brought the company to this inflection point, and the specific catalysts that could drive significant stock appreciation in 2026. The analysis covers everything from procedure economics and competitive positioning to balance sheet strength and institutional ownership patterns. Whether evaluating PROCEPT as a potential portfolio addition or simply seeking to understand why some analysts believe this robotics stock is materially undervalued, the following sections provide a comprehensive framework for assessment.
Table of Contents
- What Makes PROCEPT BioRobotics Stock Undervalued Compared to Other Robotics Companies?
- The Technology Behind PROCEPT’s AQUABEAM Robotic System and Aquablation Therapy
- Revenue Growth and Financial Trajectory Heading Into 2026
- Competitive Landscape and PROCEPT’s Defensive Moat in Surgical Robotics
- Institutional Ownership and Market Sentiment for PROCEPT Stock in 2026
- Key Catalysts That Could Drive PROCEPT Stock Higher in 2026
- How to Prepare
- How to Apply This
- Expert Tips
- Conclusion
- Frequently Asked Questions
What Makes PROCEPT BioRobotics Stock Undervalued Compared to Other Robotics Companies?
The primary reason PROCEPT Biorobotics trades at a discount relative to its growth profile and market opportunity stems from its position outside the mainstream surgical robotics conversation. When investors discuss robotic surgery, they typically reference Intuitive Surgical’s da Vinci systems or perhaps Stryker’s Mako platform for orthopedics. PROCEPT occupies a specialized niche in urology, which means it receives less coverage from generalist healthcare analysts and almost no attention from technology-focused robotics investors. This lack of visibility creates an information asymmetry that value-oriented investors can potentially exploit.
From a financial metrics standpoint, PROCEPT demonstrates characteristics typically associated with much higher valuations in the robotics sector. The company reported revenue growth exceeding 70 percent year-over-year through much of 2024 and 2025, with gross margins improving toward the 60 percent range as manufacturing scale increased. The installed base of AQUABEAM systems has grown from approximately 200 units in early 2023 to over 400 units by late 2025, with each system generating recurring revenue through disposable handpieces required for every procedure. This razor-and-blade business model, proven successful by Intuitive Surgical over two decades, provides predictable revenue streams that should command premium multiples.
- **Limited analyst coverage** creates pricing inefficiency, with fewer than 15 analysts actively covering the stock compared to 30+ for Intuitive Surgical
- **Niche market positioning** leads to exclusion from many healthcare and robotics ETFs, reducing passive investment flows
- **Pre-profitability status** deters income-focused investors despite clear pathway to operating leverage
- **Small market capitalization** (approximately $2-3 billion) falls below thresholds for many institutional mandates
The Technology Behind PROCEPT’s AQUABEAM Robotic System and Aquablation Therapy
Understanding PROCEPT’s potential requires grasping what makes its technology genuinely differentiated rather than merely incremental. The AQUABEAM robotic System combines real-time ultrasound imaging, robotic precision, and waterjet ablation to remove prostate tissue causing BPH symptoms. Unlike traditional transurethral resection of the prostate (TURP) or laser-based procedures that rely heavily on surgeon skill and experience, Aquablation uses autonomous robotics to execute a pre-planned resection with submillimeter accuracy. The surgeon maps the treatment area using integrated imaging, confirms the plan, and the robot executes the tissue removal””a fundamentally different paradigm than manually operated surgical tools.
The clinical advantages of this approach have been validated through extensive trial data. The WATER and WATER II clinical studies demonstrated that Aquablation achieved durable symptom relief with significantly lower rates of irreversible sexual dysfunction compared to TURP, the longstanding gold standard. For patients, this translates to faster recovery times, shorter hospital stays, and preservation of ejaculatory function in the majority of cases. The procedure typically takes 4-8 minutes of active treatment time regardless of prostate size, compared to TURP procedures that can extend well beyond an hour for larger prostates. This consistency and efficiency creates compelling economics for hospitals and ambulatory surgery centers.
- **Heat-free ablation** eliminates thermal damage to surrounding tissue, reducing complications
- **Size-independent procedure time** allows treatment of prostates up to 150cc or larger without proportionally increased operative time
- **Reproducible outcomes** reduce the learning curve compared to technique-dependent procedures
- **Integrated imaging and planning** allows precise tissue removal while preserving critical anatomical structures
Revenue Growth and Financial Trajectory Heading Into 2026
PROCEPT’s financial performance over the past three years tells a story of accelerating adoption and improving unit economics. Revenue grew from approximately $78 million in 2022 to roughly $140 million in 2023, then surged past $240 million in 2024. Consensus estimates for 2025 project revenue approaching $350-380 million, with 2026 estimates ranging from $480-550 million depending on the pace of new system placements and procedure volume growth at existing sites. This growth rate, sustained over multiple years, indicates genuine market pull rather than temporary factors.
The path to profitability has become increasingly visible as the company scales. Gross margins have expanded from the low 50s to approaching 60 percent, with management guiding toward eventual gross margins in the 65-70 percent range consistent with mature medical device companies. Operating expenses, while still substantial given ongoing commercial expansion and clinical development, have grown more slowly than revenue, demonstrating operating leverage. Several analysts project PROCEPT could achieve operating profitability on a non-GAAP basis by late 2026 or early 2027, a milestone that typically catalyzes multiple expansion for growth-stage medical device companies.
- **Procedure volumes** growing faster than system placements, indicating increasing utilization per machine
- **Average selling prices** remaining stable despite competitive pressures, reflecting genuine value delivered
- **International expansion** beginning in earnest, with European and Asian markets representing significant greenfield opportunity
- **Recurring revenue mix** increasing as the installed base matures, improving revenue predictability
Competitive Landscape and PROCEPT’s Defensive Moat in Surgical Robotics
The competitive dynamics in the BPH treatment market work significantly in PROCEPT’s favor compared to other surgical robotics segments. Unlike general surgery, where Intuitive faces emerging competition from Medtronic’s Hugo system, Johnson & Johnson’s Ottava, and various Chinese manufacturers, the specialized nature of Aquablation therapy creates substantial barriers to entry. Developing a competing waterjet ablation platform would require years of R&D, extensive clinical trials, and the challenge of convincing urologists to switch from an established robotic system””all while PROCEPT continues extending its lead. The more relevant competitive comparison for PROCEPT involves alternative BPH treatments rather than other robotic platforms.
Traditional TURP remains common but carries higher complication rates and longer recovery times. Rezum water vapor therapy and UroLift prostatic lifting procedures represent minimally invasive alternatives, but clinical data suggests less durable symptom relief, particularly for larger prostates. Pharmaceutical management with alpha-blockers or 5-alpha reductase inhibitors provides temporary relief but does not address the underlying tissue obstruction. PROCEPT’s positioning against these alternatives rather than against other surgical robots expands its addressable market considerably.
- **Patent protection** extending through the late 2030s on core technology components
- **Clinical evidence base** exceeding five years of published outcomes data
- **Surgeon training infrastructure** creating switching costs once physicians complete the learning curve
- **First-mover advantage** in autonomous tissue resection for urological applications
Institutional Ownership and Market Sentiment for PROCEPT Stock in 2026
Examining the ownership structure of PROCEPT reveals interesting patterns that support the undervaluation thesis. Institutional ownership has increased steadily, rising from approximately 75 percent in early 2024 to over 85 percent by late 2025, indicating growing professional investor interest. Notable healthcare-focused funds including Deerfield Management, Perceptive Advisors, and Baker Brothers have built significant positions, suggesting sophisticated medical device investors see substantial upside. However, the stock remains absent from many large-cap healthcare indices and ETFs due to market capitalization constraints, limiting passive investment flows.
Short interest has fluctuated but generally remained elevated compared to medical device peers, often ranging between 8-15 percent of the float. This creates potential for short squeeze dynamics on positive catalysts but also reflects genuine skepticism from some market participants about the path to profitability and competitive threats. Analyst price targets have shown significant dispersion, with bulls projecting 50-100 percent upside and bears questioning whether procedure volumes can sustain current growth rates. This disagreement reflects the uncertainty inherent in evaluating a company still in its commercial expansion phase but also creates opportunity for investors who develop conviction through deeper analysis.
- **Insider ownership** aligned with shareholders, with management holding meaningful equity stakes
- **Secondary offerings** largely completed, reducing near-term dilution concerns
- **Convertible debt** maturing beyond 2027, providing balance sheet flexibility
- **Options market activity** showing increased call buying ahead of earnings releases
Key Catalysts That Could Drive PROCEPT Stock Higher in 2026
Several specific events and milestones could serve as catalysts for PROCEPT shares over the coming year. Clinical data presentations at major urology conferences, including updated long-term outcomes from the WATER studies and results from ongoing trials in new indications, may reinforce the durability of Aquablation’s clinical benefits. The company has also discussed pursuing expanded FDA clearances that could broaden the eligible patient population and make reimbursement more straightforward for healthcare systems.
International expansion represents another significant catalyst with concrete near-term milestones. While PROCEPT has established presence in multiple countries, the penetration rate outside the United States remains minimal. Securing reimbursement approvals in additional European markets, expanding into Japan following regulatory clearance, and building distribution infrastructure in emerging markets could each contribute meaningfully to revenue growth and multiple expansion as investors gain confidence in the global scalability of the platform.
- **Milestone**: Achievement of quarterly operating profitability
- **Milestone**: Installed base reaching 500+ active systems
- **Milestone**: Entry into new therapeutic applications beyond BPH
- **Milestone**: Potential strategic partnership or acquisition interest from larger medical device companies
How to Prepare
- **Review clinical literature and trial data** to understand the evidence supporting Aquablation’s efficacy claims. The peer-reviewed publications from WATER and WATER II trials provide objective assessments of outcomes, and subsequent real-world evidence studies offer perspective on how results translate outside controlled trial settings.
- **Analyze quarterly earnings transcripts** from the past two years to track management commentary on system placements, procedure volumes, and geographic expansion. Pay particular attention to commentary on utilization trends at existing sites, which indicates whether installed systems are generating expected procedure volumes.
- **Compare valuation metrics** against medical device peers at similar revenue scales and growth rates. Examining how companies like Nevro, Shockwave Medical (prior to acquisition), and other growth-stage medical device firms were valued relative to revenue provides context for assessing PROCEPT’s multiple.
- **Assess balance sheet strength** by examining cash position, debt maturities, and projected cash burn rate. Understanding how long the company can fund operations without additional capital raises helps evaluate dilution risk and financial flexibility.
- **Monitor competitive developments** including any emerging waterjet or robotic ablation technologies, changes in reimbursement policy for alternative BPH treatments, and strategic moves by larger urological device companies that could affect PROCEPT’s competitive position.
How to Apply This
- **Establish position sizing parameters** based on risk tolerance, recognizing that pre-profitable medical device companies carry higher volatility than established healthcare stocks. Consider whether to build positions gradually or establish full positions immediately based on current valuation assessment.
- **Identify key monitoring metrics** to track on a quarterly basis, including system placements, procedure volumes per system, gross margin trends, and operating expense growth rates. Creating a simple tracking spreadsheet allows systematic evaluation of whether the investment thesis is playing out as expected.
- **Set price targets and stop-loss levels** based on fundamental analysis rather than arbitrary percentages. Consider what valuation multiple would be appropriate if the company achieves projected 2027 revenue estimates and work backward to determine reasonable entry points.
- **Plan for volatility around binary events** including earnings releases, clinical data presentations, and FDA communications. Decide in advance whether to add to positions on weakness or reduce exposure ahead of potentially volatile catalysts based on conviction level.
Expert Tips
- **Watch procedure volume growth more closely than system placements**, as increasing utilization per machine indicates surgeon satisfaction and repeat usage patterns that drive long-term recurring revenue.
- **Track urologist feedback through medical conference presentations and published case series**, which often provide leading indicators of adoption trends before they appear in quarterly financial results.
- **Monitor reimbursement developments carefully**, as changes in Medicare coverage policy or private payer contracting could significantly accelerate or decelerate adoption patterns.
- **Consider the acquisition premium** that typically accrues to successful medical device companies with proprietary technology platforms, as larger strategic acquirers often pay 30-50 percent premiums for differentiated surgical robotics assets.
- **Evaluate management execution track record** by comparing prior guidance to actual results, which provides insight into forecasting accuracy and whether leadership tends to underpromise and overdeliver or the reverse.
Conclusion
PROCEPT BioRobotics represents a compelling case study in how market inefficiencies can create opportunities in the surgical robotics sector. The combination of differentiated technology, strong clinical evidence, rapid revenue growth, and improving unit economics provides fundamental support for higher valuations. The relative obscurity of the stock compared to larger robotics players, combined with its absence from many index funds and limited analyst coverage, creates the information asymmetry that often precedes significant price appreciation.
For investors seeking exposure to the surgical robotics megatrend beyond the obvious large-cap names, PROCEPT offers a way to participate in a company still in its growth phase with substantial market expansion ahead. The risks are real””execution challenges, competitive responses, and the inherent uncertainties of medical device commercialization all warrant consideration. However, the asymmetric upside potential if the company continues its current trajectory makes it worthy of serious evaluation by anyone building a robotics-focused portfolio for 2026 and beyond.
Frequently Asked Questions
How long does it typically take to see results?
Results vary depending on individual circumstances, but most people begin to see meaningful progress within 4-8 weeks of consistent effort. Patience and persistence are key factors in achieving lasting outcomes.
Is this approach suitable for beginners?
Yes, this approach works well for beginners when implemented gradually. Starting with the fundamentals and building up over time leads to better long-term results than trying to do everything at once.
What are the most common mistakes to avoid?
The most common mistakes include rushing the process, skipping foundational steps, and failing to track progress. Taking a methodical approach and learning from both successes and setbacks leads to better outcomes.
How can I measure my progress effectively?
Set specific, measurable goals at the outset and track relevant metrics regularly. Keep a journal or log to document your journey, and periodically review your progress against your initial objectives.
When should I seek professional help?
Consider consulting a professional if you encounter persistent challenges, need specialized expertise, or want to accelerate your progress. Professional guidance can provide valuable insights and help you avoid costly mistakes.
What resources do you recommend for further learning?
Look for reputable sources in the field, including industry publications, expert blogs, and educational courses. Joining communities of practitioners can also provide valuable peer support and knowledge sharing.
